Astrazeneca Says Got Updated Guidelines on Stemi

AstraZeneca (NYSE: AZN ) announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for use of the oral antiplatelet (OAP) medicine BRILINTA^® (ticagrelor) tablets in patients with ST-elevation myocardial infarction (STEMI) managed